RxDoctor Payments Data

Punit Sarna, MD

Cardiovascular Disease · Mountain View, CANPI 1659553923

Payments from drug & device makers

$5,159in general payments, 2019–2025

Across 209 payments — averaging $24.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$555
  • Abbott$541
  • Novartis$472
  • Johnson & Johnson$332
  • Novo Nordisk$316
  • Bardy Diagnostics, Inc.$283
  • plus $3K from 19 others

What the payments were for

  • Food & beverage$5,159100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,159 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$168,925
Medicare patients
1,253
Services billed
2,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$104,412
EntrestoSacubitril/Valsartan43$65,724
JardianceEmpagliflozin57$62,593
XareltoRivaroxaban26$39,102
Repatha SureclickEvolocumab18$14,713
Repatha SyringeEvolocumab12$10,026
Rosuvastatin Calcium251$3,885
Metoprolol Succinate245$3,832
Ezetimibe99$2,350
Atorvastatin Calcium171$2,231
Nebivolol Hcl31$1,742
Losartan Potassium125$1,388
Carvedilol104$916
Flecainide Acetate29$859
Amlodipine Besylate113$851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$261$104,41288 claims
NovartisEntresto$472$65,72443 claims
Boehringer IngelheimJardiance$210$62,59357 claims
Johnson & JohnsonXarelto$332$39,10226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Mountain View

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →